Healthcare Industry News: osteoporosis
News Release - April 25, 2007
Acceleron Pharma Appoints James Desiderio, Ph.D. as Vice President, Program ManagementDr. Desiderio's Expertise in Managing Development Programs in Companies with Multiple Products is Valuable as Acceleron's Pipeline Rapidly Expands and Advances
CAMBRIDGE, Mass.--(HSMN NewsFeed)--Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced the appointment of James Desiderio, Ph.D. as Vice President, Program Management.
"The Acceleron product pipeline is rapidly advancing and expanding. Our lead program, ACE-011 is completing a phase 1 trial and we are preparing to initiate several phase 2 trials later this year. Additionally, IND-enabling activities are underway for our second and third products. Now that Acceleron is a multi-product company, the creation of our program management function under Jim will add tremendous value to the development of these promising products," said Matthew Sherman, M.D., Chief Medical Officer of Acceleron.
"I'm thrilled to join Acceleron and lead the program management organization," said Dr. Desiderio. "Acceleron has one of the most impressive pipelines I've seen and it will be a great opportunity to lead the department responsible for the advancement of these exciting products."
Dr. Desiderio comes to Acceleron with 23 years experience in pharmaceutical R&D, including a total of 17 years in Project Management. Dr. Desiderio was previously the Executive Director and Department Head, Program Management at Idenix Pharmaceuticals and before that worked at a number of companies including Gilead Sciences and Bristol-Myers Squibb Co. Dr. Desiderio has a vast and successful track record of leading project teams responsible for drug development activities from the research stage through to global registration and commercialization, and has been closely involved in the development of more than 10 currently marketed products. Dr. Desiderio holds an M.S. degree in Veterinary Medicine and a Ph.D. in Immunology from the College of Veterinary Medicine at Cornell University.
About Acceleron Pharma
Acceleron is a privately held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel biotherapeutics that modulate the growth of bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron's scientific approach takes advantage of its unique insight on the regenerative powers of two protein families: the Growth and Differentiation Factor (GDF) and Bone Morphogenetic Protein (BMP) families. The company's lead program is an anabolic bone agent being developed to reverse bone loss in diseases such as osteoporosis and cancer. Additionally, the company is advancing several preclinical programs that increase muscle mass, control angiogenesis and inhibit fat accumulation. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company's internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. The investors in Acceleron are Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures and Venrock Associates.
Source: Acceleron Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.